peptide acylation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
The Federal Medical Center, Rochester (FMC Rochester) is a United States federal prison in Minnesota for male inmates requiring specialized or long-term medical or mental health care. It is designated as an administrative facility, which means it holds inmates of all security classifications. It is operated by the Federal Bureau of Prisons, a division of the United States Department of Justice. FMC Rochester is located in southeastern Minnesota, 2 miles (3.2 km) east of downtown Rochester.
== Personal life == Larson is married to Leslie Best. They have three children and reside in East Hartford. On February 11, 2025, while speaking on the floor of the House, Larson froze for about 30 seconds mid-sentence. His office later responded that it was likely an "adverse reaction" to new medication, and underwent tests conducted by the Attending Physician of the United States Congress. His office later clarified that Larson had experienced a complex partial seizure caused by a heart valve replacement fifteen years earlier. Larson returned to his duties and was present for voting on the House floor on February 13.
==== 1.B. β-Barrel porins and other outer membrane proteins ==== 1.B.1 General bacterial porin family 1.B.2 Chlamydial porin (CP) family 1.B.3 Sugar porin (SP) family 1.B.4 Brucella-Rhizobium porin (BRP) family 1.B.5 Pseudomonas OprP porin (POP) family 1.B.6 OmpA-OmpF porin (OOP) family 1.B.7 Rhodobacter PorCa porin (RPP) family 1.B.8 Mitochondrial and plastid porin (MPP) family 1.B.9 FadL outer membrane protein (FadL) family 1.B.10 Nucleoside-specific channel-forming outer membrane porin (Tsx) family 1.B.11 Outer membrane fimbrial usher porin (FUP) family 1.B.12 Autotransporter-1 (AT-1) family 1.B.13 Alginate export porin (AEP) family 1.B.14 Outer membrane receptor (OMR) family 1.B.15 Raffinose porin (RafY) family 1.B.16 Short chain amide and urea porin (SAP) family 1.B.17 Outer membrane factor (OMF) family 1.B.18 Outer membrane auxiliary (OMA) protein family 1.B.19 Glucose-selective OprB porin (OprB) family 1.B.20 Two-partner secretion (TPS) family 1.B.21 OmpG porin (OmpG) family 1.B.22 Outer bacterial membrane secretin (secretin) family 1.B.23 Cyanobacterial porin (CBP) family 1.B.24 Mycobacterial porin 1.B.25 Outer membrane porin (Opr) family 1.B.26 Cyclodextrin porin (CDP) family 1.B.31 Campylobacter jejuni major outer membrane porin (MomP) family 1.B.32 Fusobacterial outer membrane porin (FomP) family 1.B.33 Outer membrane protein insertion porin (Bam complex) (OmpIP) family 1.B.34 Corynebacterial porins 1.B.35 Oligogalacturonate-specific porin (KdgM) family 1.B.39 Bacterial porin, OmpW (OmpW) family 1.B.42 Outer membrane lipopolysaccharide export porin (LPS-EP) family 1.B.43 Coxiella porin P1 (CPP1) family 1.B.44 Probable protein translocating porphyromonas gingivalis porin (PorT) family 1.B.49 Anaplasma P44 (A-P44) porin family 1.B.48 Curli-like transporters 1.B.54 Intimin/Invasin (Int/Inv) or Autotransporter-3 family 1.B.55 Poly-acetyl-D-glucosamine porin (PgaA) family 1.B.57 Legionella major-outer membrane protein (LM-OMP) family 1.B.60 Omp50 porin (Omp50 Porin) family 1.B.61 Delta-proteobacterial porin (Delta-porin) family 1.B.62 Putative bacterial porin (PBP) family 1.B.66 Putative beta-barrel porin-2 (BBP2) family 1.B.67 Putative beta barrel porin-4 (BBP4) family 1.B.68 Putative beta barrel porin-5 (BBP5) superfamily 1.B.70 Outer membrane channel (OMC) family 1.B.71 Proteobacterial/verrucomicrobial porin (PVP) family 1.B.72 Protochlamydial outer membrane porin (PomS/T) family 1.B.73 Capsule biogenesis/assembly (CBA) family 1.B.78 DUF3374 electron transport-associated porin (ETPorin) family
In 1908, the Russian foreign minister, Alexander Izvolsky, offered Russian support, for the third time, for the annexation of Bosnia and Herzegovina by Austria-Hungary, in exchange for Austrian support for the opening of the Bosporus Strait and the Dardanelles to Russian warships. Austria's foreign minister, Alois von Aehrenthal, pursued this offer vigorously, resulting in the quid pro quo understanding with Izvolsky, reached on 16 September 1908 at the Buchlau Conference. However, Izvolsky made this agreement with Aehrenthal without the knowledge of Tsar Nicholas II or his government in St. Petersburg, or any of the other foreign powers including Britain, France and Serbia. Based upon the assurances of the Buchlau Conference and the treaties that preceded it, Franz Joseph signed the proclamation announcing the annexation of Bosnia-Herzegovina into the Empire on 6 October 1908. However a diplomatic crisis erupted, as both the Serbs and the Italians demanded compensation for the annexation, which the Austro-Hungarian government refused to entertain. The incident was not resolved until the revision of the Treaty of Berlin in April 1909, exacerbating tensions between Austria-Hungary and the Serbs.
Sources: en.wikipedia.org
==== Scalp hair loss ==== Flutamide has been found to be effective in the treatment of female pattern hair loss in a number of studies. In one study of 101 pre- and postmenopausal women, flutamide alone or in combination with an oral contraceptive produced a marked decrease in hair loss scores after 1 year of treatment, with maximum effect after 2 years of treatment and benefits maintained for another 2 years. In a small study of flutamide with an oral contraceptive, the medication caused an increase in cosmetically acceptance hair density in 6 of 7 women with diffuse scalp hair loss. In a comparative study, flutamide significantly improved scalp hair growth (21% reduction in Ludwig scores) in hyperandrogenic women after 1 year of treatment, whereas cyproterone acetate and finasteride were ineffective.
The three substrates of this enzyme are salutaridine, reduced nicotinamide adenine dinucleotide phosphate (NADPH), and a proton. Its products are salutaridinol and oxidised NADPH+. This conversion is part of the morphinan alkaloid pathway in Papaver somniferum. The enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is salutaridinol:NADP+ 7-oxidoreductase.
==== Full and mini inteins ==== Inteins can contain a homing endonuclease gene (HEG) domain in addition to the splicing domains. This domain is responsible for the spread of the intein by cleaving DNA at an intein-free allele on the homologous chromosome, triggering the DNA double-stranded break repair (DSBR) system, which then repairs the break, thus copying the intein-coding DNA into a previously intein-free site. The HEG domain is not necessary for intein splicing, and so it can be lost, forming a minimal, or mini, intein. Several studies have demonstrated the modular nature of inteins by adding or removing HEG domains and determining the activity of the new construct.
Fluorescence detection can also be used in capillary electrophoresis for samples that naturally fluoresce or are chemically modified to contain fluorescent tags. This mode of detection offers high sensitivity and improved selectivity for these samples, but cannot be utilized for samples that do not fluoresce. Numerous labeling strategies are used to create fluorescent derivatives or conjugates of non-fluorescent molecules, including proteins and DNA. The set-up for fluorescence detection in a capillary electrophoresis system can be complicated. The method requires that the light beam be focused on the capillary, which can be difficult for many light sources. Laser-induced fluorescence has been used in CE systems with detection limits as low as 10−18 to 10−21 mol. The sensitivity of the technique is attributed to the high intensity of the incident light and the ability to accurately focus the light on the capillary. Multi-color fluorescence detection can be achieved by including multiple dichroic mirrors and bandpass filters to separate the fluorescence emission amongst multiple detectors (e.g., photomultiplier tubes), or by using a prism or grating to project spectrally resolved fluorescence emission onto a position-sensitive detector such as a CCD array. CE systems with 4- and 5-color LIF detection systems are used routinely for capillary DNA sequencing and genotyping ("DNA fingerprinting") applications.
=== Casting === In February 2025, Jessica Lange, who starred in the first four seasons and briefly appeared in the eight season in 2018, answered a question about her potential return for the thirteenth season: "Oh Christ, no. I mean, I haven't done it for more than 10 years, 12 years, so, no, I'm not doing it." Murphy revealed that Lange was the first person he turned to about the return and she agreed under the condition she would have a musical number. Subsequently, he turned to Sarah Paulson and Evan Peters, who agreed instantly. They both last appeared in the tenth season in 2021. In October 2025, Lange, Paulson, Peters, Emma Roberts, Billie Lourd, Kathy Bates, Angela Bassett, Leslie Grossman, Jessica Lange, and Gabourey Sidibe were all confirmed to return for the thirteenth season, along with the newcomer Ariana Grande. Bates, Bassett and Sibide last appeared in the eight season in 2018. Bates revealed that she would have only one day of filming. In February 2026, John Waters joined the cast, while Joey Pollari joined in April, and Alex Consani and Paul Anthony Kelly joined in May. John Carroll Lynch and Matt Fraser were also confirmed to reprise their roles from Freak Show, with Mena Suvari and Berto Colón also joining the cast. In July, Frances Conroy was confirmed to reprise her role from Coven, with Avantika, Grace Dumdaw, Cara Delevingne, and Charlie Carver also joining the cast. In July 2026, it was reported that Grande dropped out due to scheduling conflicts with the season's production schedule and her Eternal Sunshine Tour.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.